Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.44 |
| ▸ | HTR3B | O95264 | 2/20 | 0.44 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537469 | 0.92 | TRPV4 (0.47) | TRPV4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29636402 | 0.84 | TRPV4 (0.55) | TRPV4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2127233 | 0.84 | TRPV4 (0.55) | TRPV4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15031950 | 0.84 | HTR3E (0.45) | TRPV4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL28298273 | 0.82 | TRPV4 (0.53) | TRPV4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2477899 | 0.79 | TSHR (0.49) | ALDH1A1KDM4EMEN1KMT2ASLC6A2 | |
| SCHEMBL624403 | 0.77 | TSHR (0.47) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4289243 | 0.77 | CYP3A4 (0.45) | TRPV4LMNAALDH1A1SLC6A4KCNH2 | |
| SCHEMBL4350642 | 0.77 | TRPV4 (0.48) | TRPV4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL188251 | 0.77 | ACHE (0.71) | LMNAALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12291502-B2 | Topoisomerase II-alpha inhibitors and methods of treating cancer using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230105776-A1 | Topoisomerase II-alpha Inhibitors and Methods of Treating Cancer Using the Same | UNITED STATES GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2020205991-A1 | TOPOISOMERASE II-alpha INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-10-08 | — | — | WO | disclosed |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2004016615-A1 | PYRAZOLO (4,3c) CINNOLINE COMPOUNDS AS INHIBITORS OF ITK KINASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-20030225042-A1 | Antipicornaviral compounds and compositions, their uses, and materials for their synthesis | JOHNSON THEODORE O (US) | 2003-12-04 | — | — | US | disclosed |
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1274682-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-15 | — | — | EP | disclosed |
| US-20020006943-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001079167-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | TRPV4 2159/4885HTR3E 1207/4885HTR3B 306/4885 |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | TRPV4 4621/4885HTR3E 2568/4885HTR3B 1598/4885 |
| US-20230105776-A1 | Topoisomerase II-alpha Inhibitors and Methods of Treating Cancer Using the Same | TOP2A, TOP1, TOP2B | TRPV4 4557/4885HTR3E 4220/4885HTR3B 3890/4885 |
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | TRPV4 4456/4885HTR3E 3581/4885HTR3B 3310/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | TRPV4 4621/4885HTR3E 2568/4885HTR3B 1598/4885 |
| US-12291502-B2 | Topoisomerase II-alpha inhibitors and methods of treating cancer using the same | TOP2A, TOP1, TOP2B | TRPV4 4557/4885HTR3E 4220/4885HTR3B 3890/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | TRPV4 4621/4885HTR3E 2568/4885HTR3B 1598/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | TRPV4 4840/4885HTR3E 2961/4885HTR3B 2988/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | TRPV4 4864/4885HTR3E 926/4885HTR3B 888/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | TRPV4 159/4885HTR3E 188/4885HTR3B 144/4885 |
| US-20030225042-A1 | Antipicornaviral compounds and compositions, their uses, and materials for their synthesis | RNASEL, SARNP, RNASEH1 | TRPV4 4095/4885HTR3E 3632/4885HTR3B 4057/4885 |
| US-20020006943-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SERPINB1 | TRPV4 3769/4885HTR3E 3310/4885HTR3B 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.